Questcor Pharmaceuticals (QCOR) Announces Commercial Plans for H.P. Acthar Gel
Tweet Send to a FriendGet Alerts QCOR Hot Sheet
Price: $37.34 +1.30%
Overall Analyst Rating:
NEUTRAL (= Flat)
Dividend Yield: 2.9%
Revenue Growth %: +40.7%
Overall Analyst Rating:
NEUTRAL (= Flat)
Dividend Yield: 2.9%
Revenue Growth %: +40.7%
Trade QCOR Now!
Questcor Pharmaceuticals, Inc. (NASDAQ: QCOR) announced key elements of the Company's initial commercialization plans for H.P. Acthar Gel (repository corticotropin injection) in the treatment of rheumatology-related indications already included on the FDA-approved package insert for Acthar.
Questcor's initial commercial plans for Acthar in rheumatology include the following: 1) Creation of a Rheumatology Sales Force with 12 experienced rheumatology reps, a national sales director and two regional sales managers; 2) Commencement of a pilot rheumatology selling effort in mid-July 2012 with an initial focus on the rare and closely related neuromuscular disorders dermatomyositis (DM) and polymyositis (PM); 3) Potential expansion of the Rheumatology Sales Force following evaluation of results from the pilot effort; 4) Potential roll-out in late 2012 of a DM/PM selling effort by Questcor's current Neurology Sales Force to as many as 1,000 neurologists specializing in neuromuscular disease.
Join StreetInsider.com FREE and get immediately alerted when news breaks on your stocks and other market items - JOIN NOW
*NEW - Download StreetInsider's FREE iPhone and iPad App - Click Here
Questcor's initial commercial plans for Acthar in rheumatology include the following: 1) Creation of a Rheumatology Sales Force with 12 experienced rheumatology reps, a national sales director and two regional sales managers; 2) Commencement of a pilot rheumatology selling effort in mid-July 2012 with an initial focus on the rare and closely related neuromuscular disorders dermatomyositis (DM) and polymyositis (PM); 3) Potential expansion of the Rheumatology Sales Force following evaluation of results from the pilot effort; 4) Potential roll-out in late 2012 of a DM/PM selling effort by Questcor's current Neurology Sales Force to as many as 1,000 neurologists specializing in neuromuscular disease.
Join StreetInsider.com FREE and get immediately alerted when news breaks on your stocks and other market items - JOIN NOW
*NEW - Download StreetInsider's FREE iPhone and iPad App - Click Here
You May Also Be Interested In
- UPDATE: Google (GOOG) Improves Maps for Mobile
- Arkansas Best (ABFS) Changes Nonunion DB Pension Plan; Sees Material Impact
- Triple-S (GTS) Prices 5.4M Common Secondary Offering
Create E-mail Alert Related Categories
Corporate News
Login with Facebook
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
